Embla Medical hf. (OSSUY) Q2 2026 Earnings Call July 21, 2026 3:00 AM EDT
Company Participants
Sveinn Sölvason – President & CEO
Gudny Sveinsdottir – Chief Financial Officer
Conference Call Participants
Jesper Ingildsen – DNB Carnegie, Research Division
Martin Brenoe – Nordea Markets, Research Division
Tobias Nissen – Danske Bank A/S, Research Division
Yiwei Zhou – SEB, Research Division
Beatrice Fairbairn – Joh. Berenberg, Gossler & Co. KG, Research Division
Tom Rosenfeld
Presentation
Operator
At this time, I would like to welcome everyone to this Embla Medical Q2 2026 Conference Call. Today’s call is being recorded. If you have any objections, please disconnect at this time.
[Operator Instructions]
I would like to introduce President and CEO, Sveinn Solvason and CFO, Arna Sveinsdottir. Sveinn, over to you.
Sveinn Sölvason
President & CEO
Thank you very much. Good morning, and welcome to Embla Medical’s conference call to review our second quarter 2026 results. I’m Sveinn Solvason, President and CEO of Embla Medical. Joining me today are our Chief Financial Officer, Arna Sveinsdottir; and our Head of Investor Relations, Klaus Sindahl. Presentation will take approximately 15 minutes, followed by a Q&A session.
If you please turn to the next slide. The first half of 2026 was strong. We delivered good organic growth and increased profitability and solid free cash flow. Sales in the second quarter were $259 million, corresponding to 11% reported growth and 6% organic growth. Prosthetics and neuro orthotics continued to do very well with double-digit growth in the quarter. This was driven by strong execution, good volume growth in mainly EMEA and APAC and contributions from recently launched products. Bracing and Supports grew at a more modest pace and patient care declined, but we’re seeing very encouraging progress.
EBITDA margin was strong at 22% for the quarter. This was supported by the good performance in prosthetics